145 Participants Needed

Combination Chemotherapy for Acute Myeloid Leukemia

TK
Overseen ByTapan Kadia
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, prior therapy with certain drugs like hydroxyurea and cytarabine is allowed, so it's best to discuss your specific medications with the trial team.

What data supports the effectiveness of this drug combination for treating acute myeloid leukemia?

Research shows that combining venetoclax with azacitidine improves remission rates and survival in older patients with acute myeloid leukemia compared to azacitidine alone. Additionally, the combination of venetoclax and azacitidine has become a first-line therapy for elderly patients, achieving a high complete remission rate.12345

Is the combination of venetoclax and azacitidine safe for humans?

The combination of venetoclax and azacitidine has been found to have acceptable safety in patients with acute myeloid leukemia, including those who are older or have relapsed. It is generally well-tolerated, but as with any treatment, there may be side effects, and long-term safety data is still being observed.35678

What makes the combination chemotherapy with Azacitidine, Cladribine, Cytarabine, and Venetoclax unique for treating acute myeloid leukemia?

This treatment is unique because it combines multiple drugs, including venetoclax, which is known to improve remission rates and survival in older or unfit patients with acute myeloid leukemia when combined with azacitidine. The addition of cladribine and cytarabine may further enhance outcomes, offering a potentially more effective option for patients who are not candidates for standard chemotherapy.24678

What is the purpose of this trial?

This phase II trial studies how well venetoclax, cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated. Drugs used in chemotherapy, such as venetoclax, cladribine, and low dose cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax, cladribine, low dose cytarabine induction followed by cladribine, low dose cytarabine, and azacitidine consolidation may work better in treating patients with acute myeloid leukemia.

Research Team

Tapan M. Kadia | MD Anderson Cancer Center

Tapan Kadia, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults under 50 with untreated acute myeloid leukemia (AML), who can't have standard therapy. They must have normal liver and kidney function, be physically stable enough to participate, not pregnant or breastfeeding, willing to use contraception, and able to consent.

Inclusion Criteria

I understand the study's requirements and have signed the consent form.
I have AML and may have had only specific minor treatments.
I am 50 years or older, or under 50 but considered unsuitable for standard treatment.
See 2 more

Exclusion Criteria

I am of childbearing age and do not use birth control.
Participants with documented hypersensitivity to any of the components of the chemotherapy program
I have been diagnosed with acute promyelocytic leukemia.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction

Patients receive cladribine, cytarabine, and venetoclax for 28 days. A second induction cycle may be given if CR or CRi is not achieved.

4 weeks
Daily visits for drug administration

Consolidation/Maintenance

Patients receive cladribine, cytarabine, venetoclax, and azacitidine in cycles, repeating every 28 days for up to 18 cycles.

Up to 18 months
Regular visits for each cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment completion.

Every 6-12 months for 5 years

Treatment Details

Interventions

  • Azacitidine
  • Cladribine
  • Cytarabine
  • Venetoclax
Trial Overview The study tests a combination of chemotherapy drugs: Venetoclax, Cladribine, low dose Cytarabine, and Azacitidine in two phases—induction followed by consolidation—to see if they're more effective together in treating AML.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (cladribine, cytarabine, venetoclax, azacitidine)Experimental Treatment4 Interventions
See Detailed Description.

Azacitidine is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Vidaza for:
  • Acute myeloid leukemia
  • Chronic myelomonocytic leukemia
  • Myelodysplastic syndromes
🇺🇸
Approved in United States as Vidaza for:
  • Myelodysplastic syndromes
  • Chronic myelomonocytic leukemia
🇨🇦
Approved in Canada as Vidaza for:
  • Myelodysplastic syndromes
  • Acute myeloid leukemia
🇯🇵
Approved in Japan as Vidaza for:
  • Myelodysplastic syndromes
  • Acute myeloid leukemia

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Findings from Research

In a study of 6 children with refractory or relapsed acute myeloid leukemia (AML), the combination of venetoclax, azacitidine, and cladribine (VAC regimen) resulted in significant treatment responses, with 4 achieving complete remission and 1 showing partial remission.
Despite severe side effects like grade IV neutropenia and thrombocytopenia, there were no treatment-related deaths or infections, indicating that the VAC regimen is both effective and safe for this vulnerable patient group.
[Safety and the Short-Term Efficacy of Venetoclax Combined with Azacitidine Followed by Cladribine in Children with Refractory/Relapsed Acute Myeloid Leukemia].DU, WW., Liu, SX., Wang, Y., et al.[2023]
In a phase II study involving 60 older or unfit patients with newly diagnosed acute myeloid leukemia (AML), the combination of venetoclax with cladribine and low-dose cytarabine alternating with venetoclax and 5-azacitidine resulted in a high composite complete response rate of 93%.
The treatment showed promising overall survival and disease-free survival rates, with only one death occurring within 4 weeks, indicating that this regimen is effective and has a favorable safety profile for this patient population.
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.Kadia, TM., Reville, PK., Wang, X., et al.[2023]
In a study of 57 elderly patients (average age 69.9 years) with acute myeloid leukemia, the combination of venetoclax and azacitidine (VEN + AZA) showed a high overall response rate of 87.5% and a complete remission (CR) rate of 68.8%, indicating strong efficacy in this population.
The treatment was associated with a median overall survival (OS) of 11.5 months, and achieving minimal residual disease (MRD) negativity (<0.1%) was more common with VEN + AZA compared to traditional chemotherapy, although older patients (≥75 years) and those with higher ECOG scores faced more challenges in achieving MRD negativity.
Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients.Yu, H., Wang, C., Lei, Y., et al.[2023]

References

[Safety and the Short-Term Efficacy of Venetoclax Combined with Azacitidine Followed by Cladribine in Children with Refractory/Relapsed Acute Myeloid Leukemia]. [2023]
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. [2023]
Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients. [2023]
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia. [2022]
The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. [2023]
SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution. [2023]
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. [2021]
[Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience]. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security